In September The order is due to a lawsuit filed by New York Lawyer General Eric Schneiderman. The suit followed a CBS Information investigation in August into why a edition of the drug was being taken off the marketplace. CBS Evening News Forced switch maneuver spurs fit against drugmaker The New York State Attorney General offers filed a lawsuit stating the scheduled removal of a edition of the medication Namenda from the market violates an. Schneiderman claimed Actavis was discontinuing Namenda IR to be able to drive its patients to its newer patented drug in a scheme to block competition and maintain its high medication prices.Previously, Agendia’s offices and laboratory were situated in Huntington Seaside, CA. The brand new laboratory will further increase capacity to aid Agendia’s strong commercial expansion in the U.S. Market, and also the use of multiple Agendia tests in clinical research. MammaPrint, the business’s lead product and the only FDA-cleared breast cancer recurrence test, is reimbursed by a growing number of payers, today covering some 100 million lives. In addition, MammaPrint plays a central role in the initiated I-SPY 2 trial recently, which is a revolutionary breasts cancer trial and an initiative of the Biomarkers Consortium, a unique public-private partnership that includes the Drug and Food Administration, the National Institutes of Health, and major pharmaceutical companies, led by the building blocks for the National Institutes of Wellness.